Clinical Trial Update: To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer. [Phase 3]

View source ↗

Summary

Clinical trial comparing ZOLADEX 10.8 mg vs 3.6 mg in Chinese pre-menopausal ER+ HER2- early breast cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoladex (goserelin)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: WITHDRAWN